Executive Chairman of the Board, The Mark Foundation for Cancer Research
Director, MUSC Hollings Cancer Center
Charleston, South Carolina
For elucidating the role of cyclooxygenase 2 (COX-2) in colon cancer and the contributions of the lipid metabolite prostaglandin E2 (PGE2) to tissue inflammation in the etiology of colon cancer. His ground-breaking work led to the discovery of a COX-2 inhibitor that reduces polyp formation in patients with familial adenomatous polyposis. Collectively, he is recognized for his significant contributions to not only the cancer field at large, but also the AACR including his past AACR Presidency, Editor-in-Chief role on the journal Cancer Prevention Research, and his service as President and Chair of the AACR Foundation Board of Trustees.
To learn more, please visit the press release.